dc.contributorUniversidade Federal de São Paulo (UNIFESP)
dc.contributorABC Fdn
dc.creatorMoura, Joel Pereira de [UNIFESP]
dc.creatorNicolau, Sergio Mancini [UNIFESP]
dc.creatorStavale, Joao Norberto [UNIFESP]
dc.creatorSilva Pinhal, Maria Aparecida da [UNIFESP]
dc.creatorMatos, Leandro Luongo de
dc.creatorBaracat, Edmund Chada [UNIFESP]
dc.creatorLima, Geraldo Rodrigues de [UNIFESP]
dc.date.accessioned2016-01-24T13:58:56Z
dc.date.accessioned2022-10-07T20:30:30Z
dc.date.available2016-01-24T13:58:56Z
dc.date.available2022-10-07T20:30:30Z
dc.date.created2016-01-24T13:58:56Z
dc.date.issued2009-12-01
dc.identifierInternational Journal of Gynecological Cancer. Philadelphia: Lippincott Williams & Wilkins, v. 19, n. 9, p. 1494-1500, 2009.
dc.identifier1048-891X
dc.identifierhttp://repositorio.unifesp.br/handle/11600/31960
dc.identifier10.1111/IGC.0b013e3181a834a2
dc.identifierWOS:000272898400005
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/4018871
dc.description.abstractIntroduction: Studies have highlighted the changes that take place in the environment between the cell and the extracellular matrix during the process of neoplastic expansion. Several papers have associated the expression of heparanase 1 with various malignant tumors. Heparanase 2 is probably related to loss of cell adhesion.Objective: the aim of this study was to evaluate the expression of heparanase 2 in epithelial neoplasia of the ovaries and in samples of normal ovarian tissue.Methods: Seventy-five ovary specimens were analyzed and divided into 3 groups: 23 malignant and 35 benign epithelial ovarian neoplasia and 17 without ovarian disease. We used 2 methodological techniques for evaluating the immunoexpression of heparanase 2. the first followed the qualitative criterion of positive or negative in relation to enzymatic expression, and the second involved computerized quantification of this expression, performed on the same slides.Results: in the quantitative analysis, we found positivity indices for heparanase 2 expression of 72.2% and 87.3% in the samples of benign and malignant neoplasias, respectively. in these,the intensity of expression and the expression index were 147.2 and 121.2. respectively, for the benign neoplasia and 134.1 and 118.0 for the malignant neoplasia. Qualitatively, its expression was strong or moderate in 44.2% of the benign and 78.2% of the malignant tumors; its expression in all of the nonneoplastic samples was negative, with the exception of one that was weakly positive.Conclusions: Heparanase 2 is involved in neoplastic proliferation, but it was not exclusively associated with the malignant process. Furthermore, there was no difference in its expression between benign and malignant ovarian epithelial neoplasia.
dc.languageeng
dc.publisherLippincott Williams & Wilkins
dc.relationInternational Journal of Gynecological Cancer
dc.rightsAcesso aberto
dc.subjectOvarian neoplasia
dc.subjectHeparanase 2
dc.subjectExtracellular matrix
dc.subjectHeparan sulfate
dc.subjectProteoglycans
dc.titleHeparanase-2 Expression in Normal Ovarian Epithelium and in Benign and Malignant Ovarian Tumors
dc.typeArtigo


Este ítem pertenece a la siguiente institución